ArticleAdvances in pharmacological and pharmaceutical sciences2025
Buspirone Hydrochloride Polymorphism: Stability, Solubility, Flow Properties, and Manufacturing Implications.
Article in Advances in pharmacological and pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- 40 years later: completion of the structural characterization of the anxiolytic drug buspirone HCl and solid-form landscape expansion.RSC advances · 2026Article
- Buspirone Hydrochloride Polymorphism: Stability, Solubility, Flow Properties, and Manufacturing Implications.Advances in pharmacological and pharmaceutical sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Buspirone hydrochloride, an anxiolytic agent, has two interconvertible polymorphic forms that may affect its physicochemical properties and therapeutic efficacy. Despite this relevance, polymorphism is often neglected in pharmaceutical analyses, potentially leading to inconsistent results and compromised drug performance. This study investigates the polymorphism, stability, solubility, and flow properties of commercial samples of buspirone hydrochloride, focusing on how polymorphic transformations affect pharmaceutical performance. Samples from two international suppliers were stored under controlled and stress conditions (humidity and temperature) in open and closed vials. Structural characterization used Fourier-transform infrared spectroscopy, differential scanning calorimetry, and powder X-ray diffraction, while flow and density properties were determined by Carr index and Hausner ratio. Solubility of pure polymorphic Forms 1 and 2 was evaluated in physiologically relevant pH media using high-performance liquid chromatography. The Indian sample contained a mixture of Forms 1 and 2, whereas the Finnish sample consisted exclusively of Form 2. Under stress, Form 2 converted to Form 1, completely in open vials and partially in closed ones, confirming the greater thermodynamic stability of Form 1. Among the analytical methods, differential scanning calorimetry proved to be the most effective in distinguishing polymorphic forms and identifying mixtures. Both forms showed pH-dependent solubility, with peak dissolution at pH 1.2, and very poor flow properties, requiring formulation adjustments. Solubility data supported a preliminary classification of both polymorphs as Biopharmaceutics Classification System Class I or Class III, although permeability differences remain unexplored. These findings advance the understanding of buspirone hydrochloride's polymorphic properties, supporting the development of more effective formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.